These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37163252)

  • 21. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols.
    Božina N; Bilić I; Ganoci L; Šimičević L; Pleština S; Lešnjaković L; Trkulja V
    Br J Clin Pharmacol; 2022 May; 88(5):2190-2202. PubMed ID: 34780066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fluoropyrimidine-associated toxicity and DPYD variants c.85T>C, c.496A>G, and c.1236G>A: impact of haplotype.
    Medwid S; Wigle TJ; Kim RB
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):97-102. PubMed ID: 36357798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implementation of pharmacogenetic testing in oncology:
    Wu A; Anderson H; Hughesman C; Young S; Lohrisch C; Ross CJD; Carleton BC
    Front Pharmacol; 2023; 14():1257745. PubMed ID: 37745065
    [No Abstract]   [Full Text] [Related]  

  • 24. Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
    Hamzic S; Aebi S; Joerger M; Montemurro M; Ansari M; Amstutz U; Largiadèr C
    Swiss Med Wkly; 2020 Nov; 150():w20375. PubMed ID: 33232506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance-based capecitabine dose escalation after DPYD genotype-guided dosing in heterozygote DPYD variant carriers: a single-center observational study.
    Kleinjan JP; Brinkman I; Bakema R; van Zanden JJ; van Rooijen JM
    Anticancer Drugs; 2019 Apr; 30(4):410-415. PubMed ID: 30628914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
    De Falco V; Natalicchio MI; Napolitano S; Coppola N; Conzo G; Martinelli E; Zanaletti N; Vitale P; Giunta EF; Vietri MT; Vitiello PP; Ciardiello D; Marinaccio A; De Vita F; Ciardiello F; Troiani T
    Medicine (Baltimore); 2019 May; 98(21):e15759. PubMed ID: 31124962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
    Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
    ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DPYD variant testing in candidates for fluoropyrimidine treatment: A study protocol.
    Hernández-Guío A; Bernabéu-Martínez MªÁ; Corno-Caparrós A; Aznar-Saliente MªT; Bonete-Sánchez M; Calleja-Hernández MÁ
    Farm Hosp; 2021 Apr; 45(3):155-159. PubMed ID: 33941060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
    Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
    Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.
    Shakeel F; Fang F; Kwon JW; Koo K; Pasternak AL; Henry NL; Sahai V; Kidwell KM; Hertz DL
    Pharmacogenomics; 2021 Feb; 22(3):145-155. PubMed ID: 33410339
    [No Abstract]   [Full Text] [Related]  

  • 31. Poor association between dihydropyrimidine dehydrogenase (DPYD) genotype and fluoropyrimidine-induced toxicity in an Asian population.
    Kanai M; Kawaguchi T; Kotaka M; Manaka D; Hasegawa J; Takagane A; Munemoto Y; Kato T; Eto T; Touyama T; Matsui T; Shinozaki K; Matsumoto S; Mizushima T; Mori M; Sakamoto J; Ohtsu A; Yoshino T; Saji S; Matsuda F
    Cancer Med; 2023 Apr; 12(7):7808-7814. PubMed ID: 36524458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines.
    Cortejoso L; García-González X; García MI; García-Alfonso P; Sanjurjo M; López-Fernández LA
    Pharmacogenomics; 2016 Jun; 17(9):979-84. PubMed ID: 27248859
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Lešnjaković L; Ganoci L; Bilić I; Šimičević L; Mucalo I; Pleština S; Božina N
    Pharmacogenomics; 2023 Jan; 24(2):93-106. PubMed ID: 36636997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines.
    Toffoli G; Giodini L; Buonadonna A; Berretta M; De Paoli A; Scalone S; Miolo G; Mini E; Nobili S; Lonardi S; Pella N; Lo Re G; Montico M; Roncato R; Dreussi E; Gagno S; Cecchin E
    Int J Cancer; 2015 Dec; 137(12):2971-80. PubMed ID: 26099996
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
    Reizine N; Vokes EE; Liu P; Truong TM; Nanda R; Fleming GF; Catenacci DVT; Pearson AT; Parsad S; Danahey K; van Wijk XMR; Yeo KJ; Ratain MJ; O'Donnell PH
    Ther Adv Med Oncol; 2020; 12():1758835920974118. PubMed ID: 33414846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
    Stavraka C; Pouptsis A; Okonta L; DeSouza K; Charlton P; Kapiris M; Marinaki A; Karapanagiotou E; Papadatos-Pastos D; Mansi J
    Breast Cancer Res Treat; 2019 Jun; 175(2):511-517. PubMed ID: 30746637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population.
    Salmani M; Ghaderi B; Fotoohi A; Omid-Shafa'at R; Vahabzadeh Z; Fotouhi O; Abdi M
    Cancer Chemother Pharmacol; 2022 Nov; 90(5):389-397. PubMed ID: 36083300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Ruzzo A; Graziano F; Galli F; Galli F; Rulli E; Lonardi S; Ronzoni M; Massidda B; Zagonel V; Pella N; Mucciarini C; Labianca R; Ionta MT; Bagaloni I; Veltri E; Sozzi P; Barni S; Ricci V; Foltran L; Nicolini M; Biondi E; Bramati A; Turci D; Lazzarelli S; Verusio C; Bergamo F; Sobrero A; Frontini L; Menghi M; Magnani M
    Br J Cancer; 2017 Oct; 117(9):1269-1277. PubMed ID: 29065426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implementing DPYD*2A Genotyping in Clinical Practice: The Quebec, Canada, Experience.
    Jolivet C; Nassabein R; Soulières D; Weng X; Amireault C; Ayoub JP; Beauregard P; Blais N; Carrier C; Cloutier AS; Desnoyers A; Lemay AS; Lemay F; Loungnarath R; Jolivet J; Letendre F; Tehfé M; Vadnais C; Viens D; Aubin F
    Oncologist; 2021 Apr; 26(4):e597-e602. PubMed ID: 33274825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Upfront DPYD Genotype-Guided Treatment for Fluoropyrimidine-Based Chemotherapy in Advanced and Metastatic Colorectal Cancer: A Cost-Effectiveness Analysis.
    Fariman SA; Jahangard Rafsanjani Z; Hasanzad M; Niksalehi K; Nikfar S
    Value Health Reg Issues; 2023 Sep; 37():71-80. PubMed ID: 37329861
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.